Lee’s Pharma Socazolimab Receives NMPA’s Breakthrough Therapy Designation for Treatment of Recurrent or Metastatic Cervical Cancer

 Lee’s Pharma Socazolimab Receives NMPA’s Breakthrough Therapy Designation for Treatment of Recurrent or Metastatic Cervical Cancer

Lee’s Pharma Socazolimab Receives NMPA’s Breakthrough Therapy Designation for Treatment of Recurrent or Metastatic Cervical Cancer

Shots:

  • NMPA has granted BTD to socazolimab for cervical cancer. Socazolimab is licensed from Sorrento to COF for the greater China territory
  • Lee intends to file an NDA to the NMPA and request a fast-track conditional approval of socazolimab to treat cervical cancer in Q2’21. Additionally, the companies are planning to expand their partnership for the license of additional therapeutic antibodies from Sorrento’s G-MAB library to treat hematologic and solid tumors
  • Socazolimab is a fully human anti-PD-L1 mAb and has demonstrated outstanding efficacy and safety profile in the clinical trials in cervical cancer patients

Click here ­to­ read full press release/ article | Ref: Sorrento | Image: News Medical

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post